全文获取类型
收费全文 | 296894篇 |
免费 | 27632篇 |
国内免费 | 17451篇 |
专业分类
耳鼻咽喉 | 2745篇 |
儿科学 | 3674篇 |
妇产科学 | 5100篇 |
基础医学 | 33673篇 |
口腔科学 | 5742篇 |
临床医学 | 38236篇 |
内科学 | 44254篇 |
皮肤病学 | 3607篇 |
神经病学 | 15149篇 |
特种医学 | 10289篇 |
外国民族医学 | 128篇 |
外科学 | 30266篇 |
综合类 | 47418篇 |
现状与发展 | 54篇 |
一般理论 | 40篇 |
预防医学 | 20488篇 |
眼科学 | 7853篇 |
药学 | 31787篇 |
294篇 | |
中国医学 | 16954篇 |
肿瘤学 | 24226篇 |
出版年
2024年 | 869篇 |
2023年 | 3989篇 |
2022年 | 10937篇 |
2021年 | 14282篇 |
2020年 | 10719篇 |
2019年 | 9356篇 |
2018年 | 9999篇 |
2017年 | 9263篇 |
2016年 | 8531篇 |
2015年 | 13244篇 |
2014年 | 16502篇 |
2013年 | 15976篇 |
2012年 | 23271篇 |
2011年 | 25129篇 |
2010年 | 16599篇 |
2009年 | 13188篇 |
2008年 | 17151篇 |
2007年 | 16644篇 |
2006年 | 15862篇 |
2005年 | 14965篇 |
2004年 | 10143篇 |
2003年 | 9211篇 |
2002年 | 7627篇 |
2001年 | 6482篇 |
2000年 | 6450篇 |
1999年 | 6317篇 |
1998年 | 3497篇 |
1997年 | 3440篇 |
1996年 | 2696篇 |
1995年 | 2621篇 |
1994年 | 2330篇 |
1993年 | 1374篇 |
1992年 | 2118篇 |
1991年 | 1869篇 |
1990年 | 1532篇 |
1989年 | 1382篇 |
1988年 | 1267篇 |
1987年 | 1020篇 |
1986年 | 799篇 |
1985年 | 667篇 |
1984年 | 370篇 |
1983年 | 326篇 |
1982年 | 186篇 |
1981年 | 213篇 |
1980年 | 144篇 |
1979年 | 243篇 |
1978年 | 161篇 |
1977年 | 132篇 |
1974年 | 138篇 |
1972年 | 106篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
81.
舌癌患者手术及放化疗后会出现构音障碍、吞咽困难、口腔黏膜炎、口干、营养不良等并发症,使患者生存质量下降,甚至导致肿瘤的复发转移,影响生存期,单一方法往往顾此失彼。依托于中国中医科学院西苑医院肿瘤康复基地,杨宇飞教授在国内外调研考察基础上,结合中国国情,构建了一种“门诊多学科肿瘤康复模式”,在舌癌康复方面,以患者为中心,以中医肿瘤内科为主导,多学科共同参与,结合康复科、口腔科、营养科、药剂科等各科优势,形成全程个体化规范序贯康复方案,对患者及早进行康复,在放疗前进行预防性干预尤其重要,使患者能够快速缓解手术和放疗的不良反应,患者获益明显。现取两个典型案例总结其舌癌多学科康复的经验,以期为舌癌的康复提供借鉴。 相似文献
82.
83.
84.
The analysis of quality of life (QoL) data can be challenging due to the skewness of responses and the presence of missing data. In this paper, we propose a new weighted quantile regression method for estimating the conditional quantiles of QoL data with responses missing at random. The proposed method makes use of the correlation information within the same subject from an auxiliary mean regression model to enhance the estimation efficiency and takes into account of missing data mechanism. The asymptotic properties of the proposed estimator have been studied and simulations are also conducted to evaluate the performance of the proposed estimator. The proposed method has also been applied to the analysis of the QoL data from a clinical trial on early breast cancer, which motivated this study. 相似文献
85.
Li Sun Zia Sadique Isabel dos-Santos-Silva Li Yang Rosa Legood 《International journal of cancer. Journal international du cancer》2019,144(10):2596-2604
In low and middle-income countries mammographic breast cancer screening is prohibitively expensive and a cheaper alternative option is to use ultrasound as the primary screening test. In 2009, China launched a breast cancer screening programme for rural women aged 35–64 years with clinical breast examination coupled with ultrasound as the primary tool. Our study aimed to analyse the cost-effectiveness of breast screening compared to no screening among Chinese rural women. We developed a Markov model to estimate the lifetime costs and effects for rural women aged 35 years from a societal perspective. Asymptomatic women in the intervention arm were screened every 3 years before age 64 years. Breast cancer in the non-screening arm can only be diagnosed on presentation of symptoms. Parameter uncertainty was explored using one-way and probabilistic sensitivity analyses. Compared to no screening, breast cancer screening cost $186.7 more and led to a loss of 0.20 quality-adjusted life years (QALYs). Breast screening was more expensive and did harm to health among rural women with an incremental cost-effectiveness ratio (ICER) of $-916/QALY. The sensitivity analysis identified utility loss from false positives as the factor that most influenced the results, but this did not affect the conclusions. In a rural setting with such low breast cancer incidence, screening for asymptomatic disease is not cost-effective with current screening tools. Priority should be given to ensure that symptomatic women have proper access to diagnosis and treatment at an early stage as this will lead to mortality reductions without the usual screening harms. 相似文献
86.
87.
88.
Inflammation - Inflammation is an immune response to exogenous or endogenous insults that helps to maintain the tissue homeostasis under stressful conditions. Depending on the differential types of... 相似文献
89.
Katie Mycock Lin Zhan Gavin Taylor-Stokes Gary Milligan Debanjali Mitra 《Current oncology (Toronto, Ont.)》2021,28(1):678
Background: Palbociclib is a selective cyclin-dependent kinase (CDK) 4/6 inhibitor used in combination with aromatase inhibitors or fulvestrant for patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2 (HER2)-negative advanced/metastatic breast cancer (ABC/MBC). Palbociclib was the first CDK 4/6 inhibitor approved for HR+/HER2− ABC/MBC treatment in Canada in combination with letrozole (P+L) as an initial endocrine-based therapy (approved March 2016), or with fulvestrant (P+F) following disease progression after prior endocrine therapy (approved May 2017). The Ibrance Real World Insights (IRIS) study () collected real-world outcomes data for palbociclib-treated patients in several countries, including Canada. Methods: This retrospective chart review included women with HR+/HER2− ABC/MBC receiving P+L or P+F in Canada. Physicians reviewed medical records for up to 14 patients, abstracting demographic and clinical characteristics, treatment patterns, and clinical outcomes. Progression-free rates (PFRs) and survival rates (SRs) at 6, 12, 18, and 24 months were estimated via Kaplan–Meier analysis. Results: Thirty-three physicians examined medical records for 247 patients (P+L, n = 214; P+F, n = 33). Median follow-up was 8.8 months for P+L and 7.0 months for P+F. Most patients were initiated on palbociclib 125 mg/d (P+L, 90.2%; P+F, 84.8%). Doses were reduced in 16.6% of P+L and 14.3% of P+F patients initiating palbociclib at 125 mg/d. The PFR for P+L was 90.3% at 12 months and 78.2% at 18 months; corresponding SRs were 95.6% and 93.0%. For P+F, 6-month PFR was 91.0%; 12-month SR was 100.0%. Conclusions: Dose reduction rates were low and PFR and SR were high in this Canadian real-world assessment of P+L and P+F treatments, suggesting that palbociclib combinations are well tolerated and effective. NCT03159195相似文献
90.
Yang Chih-Hsiang Wang Shirlene Wang Wei-Lin Belcher Britni R. Dunton Genevieve F. 《Journal of behavioral medicine》2022,45(5):702-715
Journal of Behavioral Medicine - Understanding associations between mothers’ and children’s physical activity and sedentary behavior on more fine-grained timescales can provide insights... 相似文献